Peter van der Velden of Lumira Capital and a panel of Life Sciences entrepreneurs share their thoughts on the current market outlook for venture funding in the biologics space, and how they succeeded in orchestrating high-value exits for their companies.
MaRS - Building Canada’s next generation of global technology companies. marsdd.com
Loading more stuff…
Hmm…it looks like things are taking a while to load. Try again?